

# CHULARAT HOSPITAL

THAILAND / HEALTH CARE SERVICES

CHG TB

**BUY**

UNCHANGED

TARGET PRICE	THB2.18
CLOSE	THB1.72
UP/DOWNSIDE	+26.7%
PRIOR TP	THB2.60
CHANGE IN TP	-16.2%
TP vs CONSENSUS	-0.5%

## Ramping up profit growth

- Expect SSO revenue to rebound in 4Q25 from possible resumed gastric sleeve surgeries and back-to-normal high cost care rates.
- CHG's cash patient growth is underpinned by higher case intensity, hospital expansions, and resilient foreign patient volume.
- Accelerating core profit growth from 4% in 2025E to 11% in 2027E.

### A better SSO patient revenue outlook in the final quarter

We expect CHG's social security revenue to improve from 4Q25, supported by 1) resumed SSO-approved gastric surgeries from late August, potentially lifting its revenue mix from c1% to 4%; 2) pricing in the THB73m chronic disease revenue reversal in 2Q25, with accruals to drop by cTHB3.5m/quarter from 3Q25 as CHG shifts toward younger, lower-risk insured members; 3) the high-cost care rate (Adj RW>2) returning to THB12,000/RW throughout 2H25 from THB8,000 in 4Q24; and 4) a prolonged uptrend in SSO's cancer care revenue.

### Intensity and business expansions to drive cash patient wing

CHG's domestic cash patient revenue faces short-term pressure from a weak economy and soft high season, cutting the 2025 growth target from 10% to <5%. We expect its foreign patients to hold at 4-5% of revenue over three years, led by Middle East fly-ins (2%), offsetting Cambodia's drop from 0.8% to 0.4%. From 2026, self-pay growth drivers could include rising complex cases, Chularat 3 Hospital's extension in 2027 (+100 beds, or +10% of the group capacity), and a new OPD wing at Chularat 11 in 4Q25.

### Earnings growth set to accelerate


Reflecting weak 1H25 results, we have cut core profit forecasts by 9% for 2025 and 14-15% for 2026-2027. We expect 2025 core profit to grow 4% y-y to THB1.0b, with 5% cash patient revenue growth offsetting 2% SSO patient decline and a 28.3% gross margin (+1.9ppts). Core profit growth may ramp up to 9% in 2026 and 11% in 2027, based on 6% topline growth p.a. and a 0.2-0.5ppt increase in EBITDA margin as cash-patient mix rises by 0.4-0.7ppt. 2Q25 core profit is likely the bottom of this year, with 2H25 rebounding 39% h-h and 18% y-y due to SSO revenue recovery in 4Q25 and margin gains.

### Maintain our BUY call

We cut our TP to THB2.18 from THB2.60 (DCF; 8.5% WACC, 3% TG), implying 22x 2026E P/E, vs current 17x (-0.5SD), still undemanding and consistent with its local peers. CHG's strengths are 1) a strong presence in the eastern part of Bangkok; 2) having long-term potential to tap more medical tourism and ageing demand; 3) accelerating core profit in 2026-27E; and 4) solid balance sheet and moderate dividend yields. With this report, we transfer the coverage of CHG to Vatcharut Vacharawongsith.

### KEY STOCK DATA

YE Dec (THB m)	2024	2025E	2026E	2027E
Revenue	8,237	8,445	8,954	9,497
Net profit	965	1,000	1,085	1,200
EPS (THB)	0.09	0.09	0.10	0.11
vs Consensus (%)	-	(7.2)	(4.8)	(0.9)
EBITDA	1,783	1,804	1,927	2,091
Recurring net profit	965	1,000	1,085	1,200
Core EPS (THB)	0.09	0.09	0.10	0.11
Chg. In EPS est. (%)	-	(8.7)	(13.9)	(14.7)
EPS growth (%)	(7.7)	3.6	8.6	10.6
Core P/E (x)	19.6	18.9	17.4	15.8
Dividend yield (%)	4.1	3.2	3.4	3.8
EV/EBITDA (x)	10.3	10.1	9.3	8.5
Price/book (x)	2.5	2.4	2.2	2.1
Net debt/Equity (%)	(12.1)	(12.3)	(14.9)	(17.6)
ROE (%)	12.7	12.8	13.2	13.8



Share price performance	1 Month	3 Month	12 Month
Absolute (%)	(5.0)	1.8	(35.3)
Relative to country (%)	(6.2)	(9.5)	(27.5)
Mkt cap (USD m)	598		
3m avg. daily turnover (USD m)	0.9		
Free float (%)	43		
Major shareholder	Kannikar Plussind (18%)		
12m high/low (THB)	3.00/1.39		
Issued shares (m)	11,000.00		

Sources: Bloomberg consensus; FSSIA estimates


**Vatcharut Vacharawongsith**

Fundamental Investment Analyst on Securities; License no. 018301  
 vatcharut.v@fssia.com, +66 2646 9969

### Investment thesis

CHG's 4Q25 y-y earnings growth outlook improves with resumed SSO gastric sleeve surgeries, higher high-cost care rates, and continued cancer care growth, supporting a rebound in social security revenue after weakness in 1H25.

Despite short-term pressure on domestic cash patients, CHG's long-term growth is underpinned by higher case intensity, hospital expansions, and resilient foreign patient volume.

Core profit is set to grow 4% y-y in 2025 before accelerating to 9–11% in 2026–2027, backed by margin gains and a rising cash-patient mix.

### Company profile

CHG operates a healthcare business covering the eastern part of Bangkok and its nearby provinces. The Group owns nine hospitals and four clinics.


[www.chularat.com](http://www.chularat.com)

### Principal activities (revenue, 2024)

Cash patient revenue - 65.6 %

SSO patient revenue - 30.2 %

NHSO patient revenue - 4.2 %



Source: Chularat Hospital


### Major shareholders

Kannikar Plussind - 18.1 %

Apirum Panyapol - 10.3 %

Kobkul Panyapol - 8.0 %

Others - 63.6 %



Source: Chularat Hospital

### Catalysts

Key potential growth drivers include 1) more SSO-registered members, 2) rising demand from medical tourists, and 3) an improving EBITDA margin, led by new hospitals.

### Risks to our call

Downside risks to our DCF-based target price include 1) a slowdown in Thai patient volume due to economic concerns; 2) regulatory risks from drug price and medical bill controls; and 3) SSO provision expenses following limited budgets from the SSO.

### Event calendar

Date	Event
Nov 2025	3Q25 results announcement

### Key assumptions

	2025E	2026E	2027E
SS Volume growth	3	2	1
SS revenue / patients growth	(5)	3	3
OPD Volume growth	4	3	4
OPD revenue / patient growth	1	3	3
IPD Volume growth	3	4	4
IPD revenue / patient growth	1	3	3

Source: FSSIA estimates

### Earnings sensitivity

- For every 1% increase in patient volume, we project 2025 earnings to rise by 2%, and vice versa, all else being equal.
- For every 1% increase in EBITDA margin, we project 2025 earnings to rise by 3%, and vice versa, all else being equal.

Source: FSSIA estimates

2


FINANSIA

10 SEPTEMBER 2025

## A better SSO patient revenue outlook in the final quarter


We expect an improving outlook for CHG's social security patient revenue from 4Q25 onwards, supported by 1) possible resumption of gastric sleeve surgeries for eligible patients, as SSO has begun approvals of such cases countrywide in late August – this provides upside potential, as gastric surgery revenue mix may ramp up to 4% of the total topline from c1% from only self-pay patients currently; 2) pricing in the negative impact of THB73m SSO revenue reversal for chronic disease treatments in 2Q25 as CHG has replaced a number of high-risk insured Thai members with lower-risk younger foreign members – the company may reduce the accrual revenue for 26 chronic diseases by cTHB3.5m/quarter from 3Q25; 3) the return of high-cost care reimbursement rate (Adj RW>2), backing to THB 12,000/RW from THB 8,000 in 4Q24; and 4) an uptrend revenue from SSO's cancer treatment program, with higher reimbursement rates.

Exhibit 1: SSO revenue, yearly



Sources: CHG; FSSIA estimates

Exhibit 2: SSO revenue, quarterly




Sources: CHG; FSSIA's compilation


## Intensity and business expansions to drive cash patient wing

In addition to the weak performance of social security patient revenue, CHG's domestic cash patient segment may experience short-term pressure from the sluggish economy and unfavorable high season for medical care this year. The factors led management to slash the full-year 2025 topline growth target from 10% to below 5%. Meanwhile, we expect its international patient mix to be steady at 4–5% of total revenue over the next three years, versus the company's long-term target of 10%, which would be mainly driven by growth in "fly-in" patients from the Middle East (2% of total revenue) – particularly from Qatar, in addition to Oman and the UAE. This should help offset the temporary decline in patient volume from Cambodia, whose revenue contribution minimally dropped from 0.8% to 0.4%. However, it may recover in the near term as the Thai-Cambodian border situation stabilizes.

From 2026, we anticipate tailwinds for CHG's self-pay patients including 1) a rising trend in complex cases, i.e., cardiac, oncology, and neurological treatments, which may help expanding the topline from a low 2025 base; 2) planned opening of Chularat 3 Hospital's extension in 2027, which will add 100 new beds (a 42% increase in the campus's capacity and c10% for the group) – it should improve the operating leverage and help the campus turn profitable rapidly. Additionally, the site would enhance the ability to serve high-margin foreign patients with stronger revenue intensity; and 3) planned opening of a new outpatient building at Chularat 11 Hospital in 4Q25, to further support capacity and service expansions. However, CHG's new greenfield hospital project in Rayong – slated to open in 2027 with an initial phase of 59 beds out of a planned 200 – could meet a rising healthcare demand in Thailand's eastern seaboard region in the longer term, and management expects it to turn profitable within four years.

**Exhibit 3: Revenue from general patients, yearly**

Sources: CHG; FSSIA estimates

**Exhibit 4: Revenue from general patients, quarterly**

Sources: CHG; FSSIA's compilation

**Exhibit 5: Chularat 3 Hospital's facility extension**

Source: CHG

**Exhibit 6: CHG's business expansion pipeline**

Branch	2025 Existing Beds	2025-2029 Additional Beds
1. Chularat 1 Suvarnabhumi	26	-
2. Chularat 3 International	237	100 (2027)
3. Chularat 5	26	-
4. Chularat 9 Airport	139	100 (TBC)
5. Chularat 11 International	141	-
6. Chularat Cholvaej	56	-
7. Chularat Rayong	50	-
8. Chularat Rayong International	-	200 (2027)
9. Chularat 304 International	118	-
10. Ruampat Chachoengsao (RPC)	59	71+ (2H2025)
11. Chularat Mae Sot	59 (2Q23)	59+ (TBC)
12. Chularat Medical Center	27 (3Q24)	-
<b>Total</b>	<b>938</b>	<b>700+ 1,700+</b>

Source: CHG

## Earnings growth set to accelerate

To reflect CHG's weak 1H25 earnings results (-15% h-h, -5% y-y), we have revised down our core profit forecasts by 9% for 2025 and by 14-15% for 2026-2027. This is based on a 3-5% cut in revenue assumption, largely due to headwinds in the social security patient segment, including a revenue reversal in chronic disease treatments and a delay in gastric sleeve surgery approvals. We also lowered our gross margin assumptions by 0.6-1.2ppts and raised our expected SG&A/sales ratio by 0.8-1.0ppt over the three-year period.

We expect CHG's core profit to continue rising by 4% y-y in 2025 to THB1.0b, on the back of a 3% increase in total revenue. This is underpinned by a 5% growth in cash-patient revenue estimate, offset by a 2% decline in social security patient revenue forecast. Our gross margin assumption stands at 28.3% (+1.9ppts y-y), supported by a more favorable revenue mix as we expect the contribution of lower-margin SSO revenue to fall by 1.3ppts y-y to 29%.

Looking ahead, we expect CHG's core profit growth to accelerate to 9% y-y in 2026 and 11% y-y in 2027, supported by consistent 6% annual revenue growth and EBITDA margin improvements – up 0.2ppt in 2026 and 0.5ppt in 2027. Profit margin expansions would act as a key earnings growth driver. We project the cash-patient revenue mix rising by 0.4ppt y-y in 2026 and 0.7ppt y-y in 2027, thanks to the hospital capacity expansion initiatives.

In the short-term, we believe the 2Q25 core profit of THB208m (-8% q-q, +8% y-y) is likely the bottom of the year, and estimate its 2H25 core profit to rebound by 39% h-h and 18% y-y, to THB602m. In 3Q25, earnings growth should extend q-q on seasonality but decline y-y due to lower Thai self-pay patient volumes, impacted by milder seasonal epidemic trends, and a high SSO patient revenue base. At the same time, gross margin should improve q-q due to a higher mix of cash-patient revenue. For 4Q25, we foresee a development in SSO patient revenue to help core profit turn to grow y-y, despite a seasonal q-q drop.

### Exhibit 7: CHG – 2Q25 results summary

	2Q24	3Q24	4Q24	1Q25	2Q25	----- Change -----		1H24	1H25	Change	2025E	Change
	(THB m)	(THB m)	(THB m)	(THB m)	(THB m)	(q-q %)	(y-y %)	(THB m)	(THB m)	(y-y %)	(THB m)	(y-y %)
Revenue	1,985	2,309	1,921	1,988	2,012	1	1	4,007	4,000	(0)	8,445	3
Cost of sales (Incl. depreciation)	(1,559)	(1,593)	(1,418)	(1,438)	(1,464)	2	(6)	(3,057)	(2,903)	(5)	(6,058)	(0)
Gross profit	427	716	503	549	548	(0)	28	950	1,097	15	2,387	10
SG&A	(240)	(243)	(384)	(277)	(281)	1	17	(500)	(558)	12	(1,172)	4
Operating profit	186	473	119	272	267	(2)	43	450	539	20	1,215	17
Other operating income	70	74	14	30	13	(58)	(82)	156	43	(72)	73	(70)
Interest income	5	1	7	1	4	250	(19)	7	5	(17)	17	21
Equity income	(5)	(2)	(8)	(2)	(3)	26	(40)	(10)	(5)	(47)	(4)	(83)
EBIT	257	545	132	302	281	(7)	9	603	582	(3)	1,301	2
Interest expense	(9)	(9)	(8)	(8)	(7)	(7)	(18)	(17)	(15)	(15)	(34)	(3)
EBT	248	536	124	294	274	(7)	10	585	567	(3)	1,268	2
Income tax	(57)	(103)	(32)	(61)	(56)	(8)	(1)	(132)	(118)	(11)	(254)	(5)
Minority interests	0	(16)	0	(7)	(10)	35	(2,231)	3	(17)	(635)	(14)	10
Core profit	192	417	92	225	208	(8)	8	456	433	(5)	1,000	4
Extraordinaries												
Net income	192	417	92	225	208	(8)	8	456	433	(5)	1,000	4
Core EPS (THB)	0.02	0.04	0.01	0.02	0.02	(8)	8	0.04	0.04	(5)	0.09	4
No of share (m)	11,000	11,000	11,000	11,000	11,000	0	0	11,000	11,000	0	11,000	0
Cost (Excl. depreciation)	(1,434)	(1,466)	(1,292)	(1,315)	(1,338)	2	(7)	(2,812)	(2,654)	(6)	(5,542)	(1)
Depreciation & amortisation	(124)	(127)	(126)	(123)	(126)	3	2	(245)	(249)	1	(516)	4
EBITDA	381	674	259	425	405	(5)	6	851	831	(2)	1,804	1
<b>Key ratios</b>	<b>(%)</b>	<b>(%)</b>	<b>(%)</b>	<b>(%)</b>	<b>(%)</b>	<b>(ppt)</b>	<b>(ppt)</b>	<b>(%)</b>	<b>(%)</b>	<b>(ppt)</b>	<b>(%)</b>	<b>(ppt)</b>
Gross margin	22	31	26	28	27	(0)	6	24	27	4	28	2
SG&A/Revenue	12	11	20	14	14	0	2	12.5	14	1	14	0
EBITDA margin	19	28	13	21	20	(1)	1	20	21	0	21	(0)
Net profit margin	10	18	5	11	10	(1)	1	11	11	(1)	12	0
<b>Operating stats</b>	<b>(y-y %)</b>	<b>(y-y %)</b>	<b>(y-y %)</b>	<b>(y-y %)</b>	<b>(y-y %)</b>							
SSO revenue	(2)	27	(27)	(3)	(5)							
SSO registered members ('000)	542	545	546	557	562							
SSO revenue per head	(5)	23	(29)	(7)	(8)							
Cash-OPD revenue	15	(3)	1	0	6							
Cash-OPD visit number	4	3	(4)	1	8							
Cash-OPD revenue per head	10	(6)	5	(1)	(2)							
Cash-IPD revenue	12	5	(1)	(3)	(0)							
Cash-IPD admission number	5	4	(5)	1	5							
Cash-IPD revenue per head	7	1	4	(4)	(5)							

Sources: CHG; FSSIA estimates




## Exhibit 8: Earnings forecast revisions

	Current			Previous			Change		
	2025E (THB m)	2026E (THB m)	2027E (THB m)	2025E (THB m)	2026E (THB m)	2027E (THB m)	2025E (%)	2026E (%)	2027E (%)
SSO registered members ('000)	560	571	577	548	559	565	2.2	2.2	2.2
SSO revenue per head (THB)	4,362	4,493	4,627	4,821	4,965	5,114	(9.5)	(9.5)	(9.5)
Cash-OPD visits number per day (no.)	3,343	3,444	3,582	3,311	3,444	3,582	1.0	0.0	0.0
Cash-OPD revenue per head (THB)	2,174	2,239	2,306	2,217	2,305	2,398	(1.9)	(2.9)	(3.8)
Cash-IPD admissions per day (no.)	267	278	289	267	278	289	0.0	0.0	0.0
Cash-IPD revenue per head (THB)	30,726	31,648	32,597	31,334	32,588	33,891	(1.9)	(2.9)	(3.8)
Revenue	8,445	8,954	9,497	8,730	9,342	9,971	(3.3)	(4.2)	(4.8)
Gross profit margin (%)	28.3	28.7	29.1	28.9	29.8	30.3	(0.6)	(1.0)	(1.2)
SG&A/sales ratio (%)	13.9	13.6	13.4	13.1	12.6	12.5	0.8	1.0	0.9
EBITDA margin (%)	21.4	21.5	22.0	22.0	23.0	23.6	(0.7)	(1.5)	(1.6)
Core profit	1,000	1,085	1,200	1,095	1,260	1,407	(8.7)	(13.9)	(14.7)


Source: FSSIA estimates

## Exhibit 9: Total patient revenue




Sources: CHG; FSSIA estimates

## Exhibit 10: Total patient revenue contribution




Sources: CHG; FSSIA estimates

## Exhibit 11: Core profit




Sources: CHG; FSSIA estimates


## Exhibit 12: Profit margins




Sources: CHG; FSSIA estimates

**Exhibit 13: ROE**


Sources: CHG; FSSIA estimates

**Exhibit 14: CHG's general patient volume trends**

Sources: CHG; FSSIA estimates

**Exhibit 15: CHG's revenue per general patient**

Sources: CHG; FSSIA estimates

**Exhibit 16: SSO registered members and revenue per head**

Sources: CHG; FSSIA estimates

## Maintain our BUY call

We revise down our DCF-derived target price to THB2.18 from THB2.60 (8.5% WACC, 3% terminal growth), implying 22x 2026E P/E – in line with CHG's 5-year historical average. The stock's valuation still looks undemanding, trading at 17x 2026E P/E (c-0.5SD), which is also comparable to the average for Thai healthcare peers.

CHG's key strengths include 1) a leading hospital operator in the eastern Bangkok and nearby provinces; 2) the middle-end hospital model with potentials to scale up capabilities to support rising healthcare demand from medical tourism and ageing society in the longer term; 3) accelerating expected core profit growth in 2026–2027, with ROE of c13% in line with its local peer; and 4) robust financial stance with a net cash position and moderate 3-4% dividend yields.

## Exhibit 17: DCF valuation

Cost of equity assumptions	(%)	Cost of debt assumptions	(%)
Risk-free rate	3.0	Pre-tax cost of debt	3.5
Market risk premium	8.5	Marginal tax rate	20.0
Stock beta	0.9		
Cost of equity, Ke	10.4	Net cost of debt, Kd	2.8
Weight applied	75.0	Weight applied	25.0
WACC	8.5		

DCF valuation estimate	(THB m)
NPV	8,450
Terminal value	14,468
Cash & liquid assets	1,823
Investments	102
Debt	(506)
Minorities	(410)
Residual ordinary equity	23,926
No. of shares (m)	11,000
Equity value per share (THB)	2.18

Source: FSSIA estimates


## Exhibit 18: Peer comparisons as of 9 September 2025

Company	BBG	Rec	----- Share price -----			Market Cap	----- PE -----		----- ROE -----		----- PBV -----		---- EV/ EBITDA ----	
			Current	Target	Upside		25E	26E	25E	26E	25E	26E	25E	26E
			(LCY)	(LCY)	(%)	(USD m)	(x)	(x)	(%)	(%)	(x)	(x)	(x)	(x)
<b>Thailand</b>														
Bangkok Dusit Med Service	BDMS TB	BUY	20.70	31.00	49.8	10,394	20.2	18.8	15.9	16.3	3.2	3.0	12.4	11.4
Bangkok Chain Hospital	BCH TB	BUY	13.30	17.20	29.3	1,048	22.4	21.0	11.2	11.5	2.5	2.4	11.0	10.3
Bumrungrad Hospital	BH TB	HOLD	186.00	193.00	3.8	4,672	19.9	19.2	25.4	23.6	4.8	4.3	13.2	12.4
Chularat Hospital	CHG TB	BUY	1.72	2.18	26.7	598	18.9	17.4	12.8	13.2	2.4	2.2	10.1	9.3
Patrangsit Healthcare Group	PHG TB	BUY	14.20	21.0	47.9	135	13.0	11.4	15.1	16.0	1.9	1.8	6.2	5.4
Praram 9 Hospital	PR9 TB	BUY	22.90	30.0	31.0	569	21.8	19.5	14.5	14.9	3.0	2.8	12.1	10.5
Thonburi Healthcare Group	THG TB	HOLD	6.90	40.0	479.7	206	24.2	18.5	3.4	4.1	0.7	0.7	10.4	9.8
Ramkhamhaeng Hospital	RAM TB	BUY	17.80	44.0	147.2	656	15.5	13.5	7.4	8.0	1.1	1.0	18.7	17.0
Srivichai Vejvivat	VIH TB	BUY	7.70	14.0	81.8	148	12.7	13.7	10.4	8.9	1.2	1.2	6.3	7.7
Rajthanee Hospital	RJH TB	n/a	13.20	n/a	n/a	122	12.3	11.5	16.6	16.1	2.0	1.8	9.2	8.4
Ekachai Medical Care	EKH TB	n/a	5.55	n/a	n/a	140	17.2	17.0	9.8	9.4	1.7	1.6	9.2	9.2
<b>Thailand average</b>						<b>18,687</b>	<b>18.0</b>	<b>16.5</b>	<b>13.0</b>	<b>12.9</b>	<b>2.2</b>	<b>2.1</b>	<b>10.8</b>	<b>10.1</b>
<b>Regional</b>														
Ramsay Health Care	RHC AU	n/a	33.57	n/a	n/a	5,112	25.0	20.3	6.0	7.0	1.5	1.4	8.8	8.2
Ihh Healthcare Bhd	IHH SP	n/a	2.07	n/a	n/a	14,937	32.3	28.3	6.5	7.1	2.0	1.9	13.9	12.5
Ryman Healthcare	RYM NZ	n/a	2.53	n/a	n/a	1,525	101.2	31.6	0.6	1.8	0.6	0.6	30.5	19.3
Apollo Hospitals Enterprise	APHS IN	n/a	7,826	n/a	n/a	12,858	58.9	46.0	20.7	21.9	11.5	9.4	31.4	25.5
Kpj Healthcare Berhad	KPJ MK	n/a	2.37	n/a	n/a	2,514	30.4	26.7	13.4	14.2	3.9	3.7	14.1	13.1
Raffles Medical Group	RFMD SP	n/a	1.01	n/a	n/a	1,468	26.8	25.5	6.5	6.9	1.8	1.7	12.4	11.7
Mitra Keluarga Karyasehat	MIKA IJ	n/a	2,350	n/a	n/a	1,959	25.6	22.7	18.0	18.4	4.5	4.0	15.3	13.6
Aier Eye Hospital Group	300015 CH	n/a	12.75	n/a	n/a	16,696	29.8	25.9	17.5	17.8	5.0	4.4	17.7	15.6
<b>Regional average</b>						<b>57,069</b>	<b>41.2</b>	<b>28.4</b>	<b>11.1</b>	<b>11.9</b>	<b>3.8</b>	<b>3.4</b>	<b>18.0</b>	<b>14.9</b>
<b>Overall average</b>						<b>75,755</b>	<b>27.8</b>	<b>21.5</b>	<b>12.2</b>	<b>12.5</b>	<b>2.9</b>	<b>2.6</b>	<b>13.8</b>	<b>12.2</b>

Sources: Bloomberg consensus; FSSIA estimates




Exhibit 19: Prospective P/E band



Sources: Bloomberg consensus; FSSIA estimates

Exhibit 20: Prospective EV/EBITDA band



Sources: Bloomberg consensus; FSSIA estimates

## Financial Statements

### Chularat Hospital

Profit and Loss (THB m) Year Ending Dec	2023	2024	2025E	2026E	2027E
Revenue	7,730	8,237	8,445	8,954	9,497
Cost of goods sold	(5,723)	(6,068)	(6,058)	(6,382)	(6,734)
<b>Gross profit</b>	<b>2,008</b>	<b>2,169</b>	<b>2,387</b>	<b>2,572</b>	<b>2,763</b>
Other operating income	284	244	73	30	31
Operating costs	(911)	(1,127)	(1,172)	(1,216)	(1,271)
<b>Operating EBITDA</b>	<b>1,822</b>	<b>1,783</b>	<b>1,804</b>	<b>1,927</b>	<b>2,091</b>
Depreciation	(441)	(497)	(516)	(541)	(568)
Goodwill amortisation	-	-	-	-	-
<b>Operating EBIT</b>	<b>1,381</b>	<b>1,286</b>	<b>1,288</b>	<b>1,386</b>	<b>1,523</b>
Net financing costs	(15)	(20)	(17)	(12)	(6)
Associates	(19)	(20)	(4)	1	3
Recurring non-operating income	(19)	(20)	(4)	1	3
Non-recurring items	0	0	0	0	0
<b>Profit before tax</b>	<b>1,346</b>	<b>1,245</b>	<b>1,268</b>	<b>1,375</b>	<b>1,520</b>
Tax	(279)	(267)	(254)	(275)	(303)
<b>Profit after tax</b>	<b>1,067</b>	<b>978</b>	<b>1,014</b>	<b>1,100</b>	<b>1,217</b>
Minority interests	(21)	(13)	(14)	(15)	(16)
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
<b>Reported net profit</b>	<b>1,046</b>	<b>965</b>	<b>1,000</b>	<b>1,085</b>	<b>1,200</b>
<b>Non-recurring items &amp; goodwill (net)</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Recurring net profit</b>	<b>1,046</b>	<b>965</b>	<b>1,000</b>	<b>1,085</b>	<b>1,200</b>
<b>Per share (THB)</b>					
Recurring EPS *	0.10	0.09	0.09	0.10	0.11
Reported EPS	0.10	0.09	0.09	0.10	0.11
DPS	0.07	0.07	0.05	0.06	0.07
Diluted shares (used to calculate per share data)	11,000	11,000	11,000	11,000	11,000
<b>Growth</b>					
Revenue (%)	(23.5)	6.6	2.5	6.0	6.1
Operating EBITDA (%)	(53.8)	(2.1)	1.1	6.9	8.5
Operating EBIT (%)	(61.3)	(6.9)	0.2	7.6	9.9
Recurring EPS (%)	(62.4)	(7.7)	3.6	8.6	10.6
Reported EPS (%)	(62.4)	(7.7)	3.6	8.6	10.6
<b>Operating performance</b>					
Gross margin inc. depreciation (%)	26.0	26.3	28.3	28.7	29.1
Gross margin exc. depreciation (%)	31.7	32.4	34.4	34.8	35.1
Operating EBITDA margin (%)	23.6	21.6	21.4	21.5	22.0
Operating EBIT margin (%)	17.9	15.6	15.3	15.5	16.0
Net margin (%)	13.5	11.7	11.8	12.1	12.6
Effective tax rate (%)	20.4	21.1	20.0	20.0	20.0
Dividend payout on recurring profit (%)	73.6	79.8	60.0	60.0	60.0
Interest cover (X)	88.7	62.0	77.6	114.5	260.1
Inventory days	20.8	20.8	19.7	19.1	19.1
Debtor days	38.5	36.6	33.5	31.6	29.8
Creditor days	60.3	57.8	57.1	55.5	55.5
Operating ROIC (%)	15.9	14.2	14.4	15.1	16.1
ROIC (%)	14.9	13.4	13.8	14.5	15.5
ROE (%)	13.9	12.7	12.8	13.2	13.8
ROA (%)	10.5	9.6	9.8	10.3	10.8

\* Pre-exceptional, pre-goodwill and fully diluted

Revenue by Division (THB m)	2023	2024	2025E	2026E	2027E
Cash patient revenue	5,025	5,402	5,646	6,020	6,449
SSO patient revenue	2,461	2,492	2,443	2,566	2,670
NHSO patient revenue	244	343	357	367	378

Sources: Chularat Hospital; FSSIA estimates

## Financial Statements

### Chularat Hospital

Cash Flow (THB m) Year Ending Dec	2023	2024	2025E	2026E	2027E
Recurring net profit	1,046	965	1,000	1,085	1,200
Depreciation	441	497	516	541	568
Associates & minorities	-	-	-	-	-
Other non-cash items	30	(20)	14	15	16
Change in working capital	435	224	(25)	(24)	(25)
<b>Cash flow from operations</b>	<b>1,951</b>	<b>1,667</b>	<b>1,504</b>	<b>1,618</b>	<b>1,760</b>
Capex - maintenance	(1,451)	(572)	(676)	(716)	(760)
Capex - new investment	-	-	-	-	-
Net acquisitions & disposals	19	20	0	0	0
Other investments (net)	-	-	-	-	-
<b>Cash flow from investing</b>	<b>(1,432)</b>	<b>(552)</b>	<b>(676)</b>	<b>(716)</b>	<b>(760)</b>
Dividends paid	(1,045)	(770)	(770)	(600)	(651)
Equity finance	0	0	0	0	0
Debt finance	(120)	(44)	(120)	(80)	(80)
Other financing cash flows	44	(9)	(14)	(15)	(16)
<b>Cash flow from financing</b>	<b>(1,121)</b>	<b>(823)</b>	<b>(904)</b>	<b>(695)</b>	<b>(747)</b>
Non-recurring cash flows	-	-	-	-	-
Other adjustments	0	0	0	0	0
<b>Net other adjustments</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Movement in cash</b>	<b>(601)</b>	<b>292</b>	<b>(76)</b>	<b>207</b>	<b>253</b>
Free cash flow to firm (FCFF)	543.33	1,149.42	862.10	929.80	1,024.47
Free cash flow to equity (FCFE)	443.25	1,062.33	694.47	806.25	903.88
<b>Per share (THB)</b>					
FCFF per share	0.05	0.10	0.08	0.08	0.09
FCFE per share	0.04	0.10	0.06	0.07	0.08
Recurring cash flow per share	0.14	0.13	0.14	0.15	0.16
Balance Sheet (THB m) Year Ending Dec	2023	2024	2025E	2026E	2027E
Tangible fixed assets (gross)	9,318	9,831	10,507	11,223	11,983
Less: Accumulated depreciation	(3,414)	(3,850)	(4,366)	(4,907)	(5,475)
<b>Tangible fixed assets (net)</b>	<b>5,903</b>	<b>5,981</b>	<b>6,141</b>	<b>6,316</b>	<b>6,508</b>
<b>Intangible fixed assets (net)</b>	<b>104</b>	<b>104</b>	<b>104</b>	<b>104</b>	<b>104</b>
Long-term financial assets	-	-	-	-	-
Invest. in associates & subsidiaries	122	102	102	102	102
Cash & equivalents	1,399	1,692	1,616	1,823	2,076
A/C receivable	874	776	776	776	776
Inventories	336	300	298	314	332
Other current assets	1,436	1,328	1,361	1,443	1,531
<b>Current assets</b>	<b>4,046</b>	<b>4,095</b>	<b>4,052</b>	<b>4,356</b>	<b>4,714</b>
Other assets	88	103	103	103	103
<b>Total assets</b>	<b>10,264</b>	<b>10,387</b>	<b>10,503</b>	<b>10,983</b>	<b>11,532</b>
Common equity	7,525	7,720	7,949	8,435	8,984
Minorities etc.	406	410	410	410	410
<b>Total shareholders' equity</b>	<b>7,931</b>	<b>8,130</b>	<b>8,360</b>	<b>8,845</b>	<b>9,394</b>
Long term debt	705	656	536	456	376
Other long-term liabilities	247	233	233	233	233
<b>Long-term liabilities</b>	<b>953</b>	<b>889</b>	<b>769</b>	<b>689</b>	<b>609</b>
A/C payable	894	869	865	912	962
Short term debt	45	50	50	50	50
Other current liabilities	442	448	459	487	516
<b>Current liabilities</b>	<b>1,381</b>	<b>1,367</b>	<b>1,374</b>	<b>1,448</b>	<b>1,529</b>
<b>Total liabilities and shareholders' equity</b>	<b>10,264</b>	<b>10,387</b>	<b>10,503</b>	<b>10,983</b>	<b>11,532</b>
Net working capital	1,311	1,086	1,111	1,135	1,160
Invested capital	7,529	7,377	7,563	7,761	7,978
* Includes convertibles and preferred stock which is being treated as debt					
<b>Per share (THB)</b>					
Book value per share	0.68	0.70	0.72	0.77	0.82
Tangible book value per share	0.67	0.69	0.71	0.76	0.81
<b>Financial strength</b>					
Net debt/equity (%)	(8.2)	(12.1)	(12.3)	(14.9)	(17.6)
Net debt/total assets (%)	(6.3)	(9.5)	(9.8)	(12.0)	(14.3)
Current ratio (x)	2.9	3.0	2.9	3.0	3.1
CF interest cover (x)	29.9	53.1	42.9	67.6	155.1
Valuation	2023	2024	2025E	2026E	2027E
<b>Recurring P/E (x) *</b>	<b>18.1</b>	<b>19.6</b>	<b>18.9</b>	<b>17.4</b>	<b>15.8</b>
<b>Recurring P/E @ target price (x) *</b>	<b>22.9</b>	<b>24.8</b>	<b>24.0</b>	<b>22.1</b>	<b>20.0</b>
Reported P/E (x)	18.1	19.6	18.9	17.4	15.8
Dividend yield (%)	4.1	4.1	3.2	3.4	3.8
Price/book (x)	2.5	2.5	2.4	2.2	2.1
Price/tangible book (x)	2.5	2.5	2.4	2.3	2.1
EV/EBITDA (x) **	10.3	10.3	10.1	9.3	8.5
EV/EBITDA @ target price (x) **	13.0	13.1	13.0	12.0	10.9
EV/invested capital (x)	2.5	2.5	2.4	2.3	2.2
* Pre-exceptional, pre-goodwill and fully diluted    ** EBITDA includes associate income and recurring non-operating income					

Sources: Chularat Hospital; FSSIA estimates

# Chularat Hospital PCL (CHG TB)

FSSIA ESG rating

★ ★

Exhibit 21: FSSIA ESG score implication

38.25 /100

Rating	Score	Implication
★★★★★	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
★★★★★	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
★★★★	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
★★★	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
★	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Sources: FSSIA estimates

Exhibit 22: ESG – peer comparison

	FSSIA	Domestic ratings						Global ratings					Bloomberg		
	ESG score	DJSI	SET ESG	SET ESG Rating	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94
BCH	39.71	--	--	--	4.00	5.00	Certified	High	48.21	--	--	27.19	18.00	3.52	47.60
BDMS	74.00	Y	Y	Y	5.00	4.00	--	Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92
BH	51.21	--	--	--	4.00	4.00	--	Medium	64.29	A	29.00	59.03	27.00	5.08	47.79
CHG	38.25	--	--	--	4.00	5.00	--	High	55.35	--	--	59.57	21.00	2.34	50.24
PR9	54.08	--	Y	Y	5.00	5.00	Certified	High	71.12	--	--	62.39	--	2.43	37.90
PRINC	18.00	--	--	--	4.00	4.00	Certified	--	--	--	--	--	--	--	--
RAM	11.75	--	--	--	3.00	--	--	High	--	--	--	--	--	--	--
THG	18.75	--	--	--	5.00	5.00	--	High	--	--	--	--	--	--	--
VIBHA	20.88	--	--	--	4.00	3.00	Declared	High	--	--	--	--	17.00	--	--

Sources: SETTRADE.com; FSSIA's compilation

Exhibit 23: ESG score by Bloomberg

FY ending Dec 31	FY 2019	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	—	—	2.21	2.34
BESG environmental pillar score	—	—	4.04	4.18
BESG social pillar score	—	—	0.74	0.79
BESG governance pillar score	—	—	4.19	4.49
ESG disclosure score	36.82	36.82	41.54	50.24
Environmental disclosure score	16.49	16.49	17.67	32.92
Social disclosure score	12.70	12.70	19.41	30.29
Governance disclosure score	81.10	81.10	87.36	87.36
Environmental				
Emissions reduction initiatives	Yes	Yes	Yes	Yes
Climate change policy	No	No	Yes	Yes
Climate change opportunities discussed	No	No	No	No
Risks of climate change discussed	No	No	No	No
GHG scope 1	0	0	0	0
GHG scope 2 location-based	4	4	4	4
GHG Scope 3	1	1	1	1
Carbon per unit of production	—	—	—	—
Biodiversity policy	No	No	No	No
Energy efficiency policy	Yes	Yes	Yes	Yes
Total energy consumption	—	—	—	—
Renewable energy use	—	—	—	—
Electricity used	4	4	4	7
Fuel used - natural gas	—	—	—	—

Sources: Bloomberg; FSSIA's compilation

**Exhibit 24: ESG score by Bloomberg (cont.)**

FY ending Dec 31	FY 2019	FY 2020	FY 2021	FY 2022
Fuel used - crude oil/diesel	No	No	No	No
Waste reduction policy	Yes	Yes	Yes	Yes
Hazardous waste	0	0	0	0
Total waste	1	1	1	1
Waste recycled	0	0	0	0
Waste sent to landfills	—	—	—	—
Environmental supply chain management	No	No	No	No
Water policy	No	No	Yes	Yes
Water consumption	89	73	80	70
<b>Social</b>				
Human rights policy	Yes	Yes	Yes	Yes
Policy against child labor	Yes	Yes	Yes	Yes
Quality assurance and recall policy	No	No	No	No
Consumer data protection policy	Yes	Yes	Yes	Yes
Equal opportunity policy	Yes	Yes	Yes	Yes
Gender pay gap breakout	No	No	No	No
Pct women in workforce	—	—	84	85
Pct disabled in workforce	—	—	—	—
Business ethics policy	Yes	Yes	Yes	Yes
Anti-bribery ethics policy	Yes	Yes	Yes	Yes
Health and safety policy	Yes	Yes	Yes	Yes
Lost time incident rate - employees	—	—	—	0
Total recordable incident rate - employees	—	—	—	—
Training policy	Yes	Yes	Yes	Yes
Fair remuneration policy	No	No	No	No
Number of employees – CSR	3,612	3,616	3,871	4,520
Employee turnover pct	—	—	20	20
Total hours spent by firm - employee training	—	—	32,904	85,880
Social supply chain management	No	No	No	No
<b>Governance</b>				
<b>Board size</b>	<b>12</b>	<b>12</b>	<b>12</b>	<b>12</b>
<b>No. of independent directors (ID)</b>	<b>4</b>	<b>4</b>	<b>4</b>	<b>4</b>
No. of women on board	2	2	2	2
No. of non-executive directors on board	11	11	11	10
Company conducts board evaluations	Yes	Yes	Yes	Yes
No. of board meetings for the year	6	7	7	6
Board meeting attendance pct	100	100	95	100
Board duration (years)	3	3	3	3
Director share ownership guidelines	No	No	No	No
Age of the youngest director	60	62	63	59
Age of the oldest director	77	78	79	80
<b>No. of executives / company managers</b>	<b>6</b>	<b>6</b>	<b>6</b>	<b>6</b>
No. of female executives	2	2	2	2
Executive share ownership guidelines	No	No	No	No
<b>Size of audit committee</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>3</b>
No. of ID on audit committee	3	3	3	3
Audit committee meetings	5	5	5	5
Audit meeting attendance %	100	100	100	100
<b>Size of compensation committee</b>	<b>5</b>	<b>5</b>	<b>5</b>	<b>5</b>
No. of ID on compensation committee	4	4	4	4
No. of compensation committee meetings	2	2	2	2
Compensation meeting attendance %	100	100	83	100
<b>Size of nomination committee</b>	<b>5</b>	<b>5</b>	<b>5</b>	<b>5</b>
No. of nomination committee meetings	2	2	2	2
Nomination meeting attendance %	100	100	83	100
<b>Sustainability governance</b>				
Verification type	No	No	No	No

Sources: Bloomberg; FSSIA's compilation

## Disclaimer for ESG scoring

ESG score	Methodology	Rating																			
The Dow Jones Sustainability Indices ( <a href="#">DJSI</a> ) By S&P Global	The DJSI World applies a transparent, rules-based component selection process based on the companies' Total Sustainability Scores resulting from the annual S&P Global Corporate Sustainability Assessment (CSA). Only the top-ranked companies within each industry are selected for inclusion.	Be a member and invited to the annual S&P Global Corporate Sustainability Assessment (CSA) for DJSI. Companies with an S&P Global ESG Score of less than 45% of the S&P Global ESG Score of the highest scoring company are disqualified. The constituents of the DJSI indices are selected from the Eligible Universe.																			
SET ESG Ratings List ( <a href="#">SETESG</a> ) by The Stock Exchange of Thailand ( <a href="#">SET</a> )	SET ESG quantifies responsibility in Environmental and Social issues by managing business with transparency in Governance, updated annually. Candidates must pass the preemptive criteria, with two crucial conditions: 1) no irregular trading of the board members and executives; and 2) free float of >150 shareholders, and combined holding must be >15% of paid-up capital. Some key disqualifying criteria include: 1) CG score of below 70%; 2) independent directors and free float violation; 3) executives' wrongdoing related to CG, social & environmental impacts; 4) equity in negative territory; and 5) earnings in red for > 3 years in the last 5 years.	To be eligible for <b>SETESG inclusion</b> , verified data must be scored at a minimum of 50% for each indicator, unless the company is a part of DJSI during the assessment year. The scoring will be fairly weighted against the nature of the relevant industry and materiality. <b>SETESG Index</b> is extended from the SET ESG Ratings companies whose 1) market capitalization > THB5b (~USD150b); 2) free float >20%; and 3) liquidity >0.5% of paid-up capital for at least 9 out of 12 months. The SETTHSI Index is a market capitalisation-weighted index, cap 5% quarterly weight at maximum, and no cap for number of stocks.																			
<b>CG Score</b> by Thai Institute of Directors Association (Thai IOD)	An indicator of CG strength in sustainable development, measured annually by the Thai IOD, with support from the Stock Exchange of Thailand (SET). The results are from the perspective of a third party, not an evaluation of operations.	Scores are rated in six categories: 5 for Excellent (90-100), 4 for Very Good (80-89), 3 for Good (70-79), 2 for Fair (60-69), 1 for Pass (60-69), and not rated for scores below 50. Weightings include: 1) the rights; 2) and equitable treatment of shareholders (weight 25% combined); 3) the role of stakeholders (25%); 4) disclosure & transparency (15%); and 5) board responsibilities (35%).																			
<b>AGM level</b> By Thai Investors Association (TIA) with support from the SEC	It quantifies the extent to which shareholders' rights and equitable treatment are incorporated into business operations and information is transparent and sufficiently disclosed. All form important elements of two out of five the CG components to be evaluated annually. The assessment criteria cover AGM procedures before the meeting (45%), at the meeting date (45%), and after the meeting (10%). <i>(The first assesses 1) advance circulation of sufficient information for voting; and 2) facilitating how voting rights can be exercised. The second assesses 1) the ease of attending meetings; 2) transparency and verifiability; and 3) openness for Q&amp;A. The third involves the meeting minutes that should contain discussion issues, resolutions and voting results.)</i>	The scores are classified into four categories: 5 for Excellent (100), 4 for Very Good (90-99), 3 for Fair (80-89), and not rated for scores below 79.																			
<a href="#">Thai CAC</a> By Thai Private Sector Collective Action Against Corruption (CAC)	The core elements of the Checklist include corruption risk assessment, establishment of key controls, and the monitoring and developing of policies. The Certification is good for three years. <i>(Companies deciding to become a CAC certified member start by submitting a Declaration of Intent to kick off an 18-month deadline to submit the CAC Checklist for Certification, including risk assessment, in place of policy and control, training of managers and employees, establishment of whistleblowing channels, and communication of policies to all stakeholders.)</i>	The document will be reviewed by a committee of nine professionals. A passed Checklist will move for granting certification by the CAC Council approvals whose members are twelve highly respected individuals in professionalism and ethical achievements.																			
<a href="#">Morningstar Sustainabilitys</a>	The Sustainabilitys' ESG risk rating provides an overall company score based on an assessment of how much of a company's exposure to ESG risk is unmanaged. <i>Sources to be reviewed include corporate publications and regulatory filings, news and other media, NGO reports/websites, multi-sector information, company feedback, ESG controversies, issuer feedback on draft ESG reports, and quality &amp; peer reviews.</i>	A company's ESG risk rating score is the sum of unmanaged risk. The more risk is unmanaged, the higher ESG risk is scored. <table><tr><th>NEGL</th><th>Low</th><th>Medium</th><th>High</th><th>Severe</th></tr><tr><td>0-10</td><td>10-20</td><td>20-30</td><td>30-40</td><td>40+</td></tr></table>	NEGL	Low	Medium	High	Severe	0-10	10-20	20-30	30-40	40+									
NEGL	Low	Medium	High	Severe																	
0-10	10-20	20-30	30-40	40+																	
<a href="#">ESG Book</a>	The ESG score identifies sustainable companies that are better positioned to outperform over the long term. The methodology considers the principle of financial materiality including information that significantly helps explain future risk-adjusted performance. Materiality is applied by over-weighting features with higher materiality and rebalancing these weights on a rolling quarterly basis.	The total ESG score is calculated as a weighted sum of the features scores using materiality-based weights. The score is scaled between 0 and 100 with higher scores indicating better performance.																			
<a href="#">MSCI</a>	MSCI ESG ratings aim to measure a company's management of financially relevant ESG risks and opportunities. It uses a rules-based methodology to identify industry leaders and laggards according to their exposure to ESG risks and how well they manage those risks relative to peers. <table><tr><td><b>AAA</b></td><td>8.571-10.000</td><td rowspan="3"><b>Leader:</b></td><td rowspan="3">leading its industry in managing the most significant ESG risks and opportunities</td></tr><tr><td><b>AA</b></td><td>7.143-8.570</td></tr><tr><td><b>A</b></td><td>5.714-7.142</td></tr><tr><td><b>BBB</b></td><td>4.286-5.713</td><td rowspan="3"><b>Average:</b></td><td rowspan="3">a mixed or unexceptional track record of managing the most significant ESG risks and opportunities relative to industry peers</td></tr><tr><td><b>BB</b></td><td>2.857-4.285</td></tr><tr><td><b>B</b></td><td>1.429-2.856</td></tr><tr><td><b>CCC</b></td><td>0.000-1.428</td><td><b>Laggard:</b></td><td>lagging its industry based on its high exposure and failure to manage significant ESG risks</td></tr></table>	<b>AAA</b>	8.571-10.000	<b>Leader:</b>	leading its industry in managing the most significant ESG risks and opportunities	<b>AA</b>	7.143-8.570	<b>A</b>	5.714-7.142	<b>BBB</b>	4.286-5.713	<b>Average:</b>	a mixed or unexceptional track record of managing the most significant ESG risks and opportunities relative to industry peers	<b>BB</b>	2.857-4.285	<b>B</b>	1.429-2.856	<b>CCC</b>	0.000-1.428	<b>Laggard:</b>	lagging its industry based on its high exposure and failure to manage significant ESG risks
<b>AAA</b>	8.571-10.000	<b>Leader:</b>	leading its industry in managing the most significant ESG risks and opportunities																		
<b>AA</b>	7.143-8.570																				
<b>A</b>	5.714-7.142																				
<b>BBB</b>	4.286-5.713	<b>Average:</b>	a mixed or unexceptional track record of managing the most significant ESG risks and opportunities relative to industry peers																		
<b>BB</b>	2.857-4.285																				
<b>B</b>	1.429-2.856																				
<b>CCC</b>	0.000-1.428	<b>Laggard:</b>	lagging its industry based on its high exposure and failure to manage significant ESG risks																		
<a href="#">Moody's ESG solutions</a>	Moody's assesses the degree to which companies take into account ESG objectives in the definition and implementation of their strategy policies. It believes that a company integrating ESG factors into its business model and relatively outperforming its peers is better positioned to mitigate risks and create sustainable value for shareholders over the medium to long term.																				
<a href="#">Refinitiv ESG rating</a>	Designed to transparently and objectively measure a company's relative ESG performance, commitment and effectiveness across 10 main themes, based on publicly available and auditable data. The score ranges from 0 to 100 on relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly. <i>(Score ratings are 0 to 25 = poor; &gt;25 to 50 = satisfactory; &gt;50 to 75 = good; and &gt;75 to 100 = excellent.)</i>																				
<a href="#">S&amp;P Global</a>	The S&P Global ESG Score is a relative score measuring a company's performance on and management of ESG risks, opportunities, and impacts compared to its peers within the same industry classification. The score ranges from 0 to 100.																				
<b>Bloomberg</b>	ESG Score	Bloomberg score evaluating the company's aggregated Environmental, Social and Governance (ESG) performance. The score is based on Bloomberg's view of ESG financial materiality. The score is a weighted generalized mean (power mean) of Pillar Scores, where the weights are determined by the pillar priority ranking. Values range from 0 to 10; 10 is the best.																			
Bloomberg	ESG Disclosure Score	Disclosure of a company's ESG used for Bloomberg ESG score. The score ranges from 0 for none to 100 for disclosure of every data point, measuring the amount of ESG data reported publicly, and not the performance on any data point.																			

[Rating](#) regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "**CG Score**"; 2) "**AGM Level**"; 3) "**Thai CAC**"; and 4) **THSI**. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation



GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Vatcharut Vacharawongsith FSS International Investment Advisory Securities Co., Ltd


The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price

Chularat Hospital (CHG TB)



Vatcharut Vacharawongsith started covering this stock from 10-Sep-2025

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Chularat Hospital	CHG TB	THB 1.72	BUY	Downside risks to our DCF-based target price include 1) a slowdown in Thai patient volume due to economic concerns; 2) regulatory risks from drug price and medical bill controls; and 3) SSO provision expenses following limited budgets from the SSO.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 09-Sep-2025 unless otherwise stated.

## RECOMMENDATION STRUCTURE

### Stock ratings

Stock ratings are based on absolute upside or downside, which we define as  $(\text{target price}^* - \text{current price}) / \text{current price}$ .

**BUY (B).** The upside is 10% or more.

**HOLD (H).** The upside or downside is less than 10%.

**REDUCE (R).** The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

\* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

### Industry Recommendations

**Overweight.** The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

**Neutral.** The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

**Underweight.** The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

### Country (Strategy) Recommendations

**Overweight (O).** Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

**Neutral (N).** Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

**Underweight (U).** Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.